Skip to main
ABSI
ABSI logo

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci Corp is positioned favorably due to its promising clinical activity with ABS-101, which could enhance the probability of success in ulcerative colitis (UC) and Crohn's disease (CD) to 15%. Strong initial results from ABS-101 could not only validate Absci's innovative platform but also attract interest from large pharmaceutical companies, highlighting the potential for significant partnerships. Additionally, the expansion of collaborations, such as with Almirall, demonstrates Absci's ability to deliver results in challenging therapeutic areas, reinforcing its growth trajectory in the biologics market.

Bears say

The analysis identifies a negative outlook on Absci Corp's stock primarily due to increased dilution resulting from a recent financing round, which has adversely affected its valuation metrics. Additionally, there are concerns regarding the standard of care in the endo sector, particularly for non-hormonal treatment options, which may limit market opportunities and investor confidence. Overall, these factors contribute to a weakened perception of the company's financial stability and future growth prospects.

Absci Corp (ABSI) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.